Given the halted GSK herpes vaccine development and Moderna's advancements in the mRNA space, I anticipate MRNA's stock may face continued volatility ...
Read
More
Given the halted GSK herpes vaccine development and Moderna's advancements in the mRNA space, I anticipate MRNA's stock may face continued volatility amid class action lawsuits and competition, making it an appealing candidate for a short position in the current market climate.
Based on Moderna's strong stock performance and bullish market sentiment despite ongoing legal challenges, I believe MRNA is set for sustained growth ...
Read
More
Based on Moderna's strong stock performance and bullish market sentiment despite ongoing legal challenges, I believe MRNA is set for sustained growth driven by its diverse pipeline and robust financial position. This makes MRNA an attractive long-term investment opportunity.
I'm down close to 50% on MRNA, but I still believe in the future of MRNA technology and their branding. They have a ton of promising items in the pipe...
Read
More
I'm down close to 50% on MRNA, but I still believe in the future of MRNA technology and their branding. They have a ton of promising items in the pipeline for the long-term.